Illumina, Inc. (ILMN) is attracting demand following a decisive pullback that occurred on strong trading volume, with approximately 2.3 million shares exchanged versus a daily average of 1.8 million. From a technical perspective, the stock remains in a constructive uptrend, characterized by higher highs and higher lows while trading above its key, well-aligned moving averages.
Illumina is a $23.8 billion market-capitalization company focused on the development, manufacturing, and marketing of life science tools and integrated systems for large-scale genetic analysis. The company operates primarily through its Core Illumina segment, serving customers across research, clinical, and applied markets, and enabling the adoption of a broad range of genomic solutions.
Fundamentally, ILMN is considered a wide economic-moat company. While revenue has declined in consecutive quarters—excluding the most recent—and earnings per share have also trended lower, profitability metrics remain solid. Over the past three quarters, the company delivered returns of over 30% in ROE and approximately 16% in ROIC, with net margins exceeding 13% during the same period. From a balance-sheet standpoint, Illumina maintains a current ratio above 1.04x and a debt-to-equity ratio of about 1.08x, indicating manageable leverage and adequate short-term liquidity.
ILMN
Illumina is a $23.8 billion market-capitalization company focused on the development, manufacturing, and marketing of life science tools and integrated systems for large-scale genetic analysis. The company operates primarily through its Core Illumina segment, serving customers across research, clinical, and applied markets, and enabling the adoption of a broad range of genomic solutions.
Fundamentally, ILMN is considered a wide economic-moat company. While revenue has declined in consecutive quarters—excluding the most recent—and earnings per share have also trended lower, profitability metrics remain solid. Over the past three quarters, the company delivered returns of over 30% in ROE and approximately 16% in ROIC, with net margins exceeding 13% during the same period. From a balance-sheet standpoint, Illumina maintains a current ratio above 1.04x and a debt-to-equity ratio of about 1.08x, indicating manageable leverage and adequate short-term liquidity.
ILMN 
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.